Annovis Bio (ANVS) to Release Earnings on Friday

Annovis Bio (NYSE:ANVS) is projected to release its earnings data before the market opens on Friday, April 4th. Analysts expect Annovis Bio to post earnings of ($0.38) per share for the quarter.

Annovis Bio (NYSE:ANVS) last announced its earnings results on Friday, March 21st. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). During the same period in the prior year, the company posted ($0.43) earnings per share. On average, analysts expect Annovis Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Annovis Bio Stock Up 7.4 %

Annovis Bio stock opened at $1.60 on Thursday. Annovis Bio has a 12-month low of $1.43 and a 12-month high of $20.00. The stock has a 50-day simple moving average of $2.47 and a 200 day simple moving average of $5.38. The stock has a market capitalization of $22.78 million, a price-to-earnings ratio of -0.36 and a beta of 1.65.

Analyst Ratings Changes

Separately, D. Boral Capital restated a “hold” rating on shares of Annovis Bio in a research report on Monday, February 10th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $37.00.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.